Senseonics Third Quarter 2026 Earnings Call - SENSEONICS HOLDINGS INC

Explicit Guidance:

• FY 2026 Revenue: Raised to $68 million – $70 million (from prior $62M–$66M).
• FY 2026 Gross Margin: Updated to north of 60%.
• FY 2026 Operating Expenses: Expected slightly above the high end of the prior $150M–$160M range (approx. $160M+).
• FY 2026 Cash Utilization: Expected at the high end of the prior range, approx. $120 million over four years.
• FY 2026 International Revenue Mix: Europe expected to represent ~15% of full-year revenue (down from prior 20% estimate) due to US outperformance.
• Reimbursement Channel Mix: Full-year expectation remains a 60-40 split between bundled pay and DME (DME/DME channel shift noted as temporary in Q3 to 65-35).
• 2027 Revenue Target: Management states they will be a $100 million company in 2027, though formal guidance to be issued in early 2027 (market consensus currently ~$100M, <50% growth vs previous projections).
• FY 2027 Q4 Margins: Q4 gross margin expected to remain close to Q3 levels (approx. 62%), with modest improvements anticipated in 2027 as scale expands and Eversense 365 operates a full year in Europe.
• Freedom Margin Profile: Expected gross margins for the "Freedom" system to be north of 70%.

Business-Segment Outlook:

• Product Adoption: Expecting the majority of new patients to continue switching from short-term competitive CGMs (approx. 9 out of 10 new insertions); retention rates exceed plan with ~94% reaching full sensor term and ~75% of first-time users re-inserting for a second sensor.
• U.S. Growth: U.S. revenue growth of ~160% YoY in Q3; sales running ahead of prior expectations with record new patient starts driven by Direct-to-Consumer (DTC) channels and expanding prescriber base (>90% YoY increase in active prescribers).
• International Expansion: Commercial transition of Essentia teams to Senseonics complete; dedicated teams leading Eversense 365 launches in Germany, Italy, Spain, and Sweden; network expanding into previously unserved areas.
• EonCare Network: Inserter network exceeded year-end goals (target 100); now tracking to reach ~120 inserters by year-end, accounting for >40% of all U.S. insertions.
• Reimbursement Mix: Bundled pay channel (higher ASP) is expected to maintain a 60-40 split vs. DME long-term; Q3 saw a temporary shift to 65% bundled pay.

Market and Competitive Outlook:

• Pump Ecosystem: Launching integration with Beta Bionics (iLet bionic pancreas) in the coming weeks; building on existing successful integration with Tandem Diabetes Care (Tandem) (Twist pump).
• Future Partnerships: Continuing conversations with other major pump companies to offer patient choice; timeline for additional partnerships (beyond Tandem and Beta) anticipated for the 2028–2030 period.
• Competitive Advantage: Positioned as the only company offering a full-year sensor with a removable transmitter; unique "no on-body component" technology differentiates the upcoming "Freedom" system.
• Patient Demand: Anticipating continued strong demand from patients seeking AID (Automated Insulin Delivery) solutions and those switching from short-term sensors due to retention and convenience.

Macro / Industry Outlook:

• Operational Leverage: Management projects cash flow break-even shortly after the launch of the Freedom system, driven by Freedom's high margin profile (70%+) and operating leverage as revenue scales.
• Financial Structure: Cash and short-term investments at $126.6M; debt under Hercules Capital facility at ~$56.2M; balance sheet viewed as sufficient to fund growth and R&D until Freedom launches.
• Regulatory/Development: First-in-human study for Freedom underway (early feasibility); pivotal study for Freedom expected to begin in 2027.
• Pricing/Channel Dynamics: Q4 gross margin stability expected despite potential seasonal shifts in patient assistance utilization (lower in Q4, higher in Q1); bundled pay ASPs noted as meaningfully higher than DME.

Strategic Initiatives:

• Freedom System Launch: Targeting potential commercial launch in 2028; product features full-year glucose data with no on-body component (integrated battery, embedded Bluetooth).
• Beta Bionics Partnership: Commercial launch of iLet integration expected in the coming weeks; first patients possible before year-end; anticipated to drive growth in 2027.
• Tandem (Twist) Partnership: Integration performing well; first year described as "fantastic"; serves as a blueprint for Beta launch.
• Mint System Integration: Planning to work side-by-side to integrate Eversense 365 with the Medtronic Mint system upon its market entry.
• Commercial Infrastructure: Completed in-house transition of global commercial operations from Essentia; focus on scaling EonCare inserter network and refining DTC conversion metrics.
• R&D Focus: Continued investment in Gemini studies (underlying Freedom tech), Freedom development, and Eversense 365 optimization.

Risks and Headwinds to Outlook:

• TSA Costs: Full-year OPEX slightly elevated due to transition service agreement (TSA) costs from the Essentia deal; however, these are expected to decline significantly in Q4 as agreements wind down.
• International Timing: European rollout took longer than expected to launch the 365-day sensor compared to the U.S., resulting in a lower 2026 international revenue contribution than initially modeled (15% vs. 20%).
• Seasonality: Q1 revenue and gross margins may face headwinds due to the reset of patient deductibles and increased utilization of patient assistance programs.
• Regulatory/Clinical: Freedom success is contingent on the pivotal study timeline; delays in 2027 would push the launch further than the 2028 target.
• Supply/Execution: Reliance on the continued expansion of the inserter network (EonCare) to support geographic growth and DTC conversion.

Management Tone on the Future:

• Confidence: "Very excited" about momentum; describes Q3 as a "breakout quarter" and the business as "growing at a remarkable pace."
• Strategic Clarity: Emphasizes "operating leverage" as the key to profitability, noting that gross profit dollars are funding continued investment in commercial org and pipeline.
• Guidance Changes: Explicitly raised full-year revenue guidance for the third time in the year, citing sales running ahead of expectations and improved execution.
• Future Focus: Frames the path to Freedom as the "top priority" for development; describes the upcoming ecosystem of pump choices and the "revolutionary" nature of Freedom.

Miscellaneous:

• Q4 Outlook: Management expects "very good" Q4 performance driven by seasonality (patients meeting deductibles) and the ramp-up of the Beta Bionics launch.
• R&D Expenses: Q3 R&D was $11.7M (up from $7.8M YoY) driven by Gemini and Freedom clinical trials; future spend will support pivotal studies and development.
• SG&A: Q3 SG&A was $32.3M (up from $15.3M YoY) reflecting in-house commercial costs; expected to step down in Q4 due to the winding down of TSA costs.